PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. We have created a broad and deep pipeline through the expertise of our experienced research and development team and our extensive network of scientists, clinicians and industry leaders.
For Investor Relations inquiries, please contact PureTech's Investor Relations team at: firstname.lastname@example.org.
View our corporate deck.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Cash at Parent Level
$341.4M PureTech Level Cash and Cash Equivalents as of June 30, 2022 1
Thomas J. Smith
SVB Leerink LLC
Jefferies International Ltd.
Peel Hunt LLP